The system can be thought of as two separate groups: the M and N antigens are at one location on the ECM and S, s, and U are on a closely related location. The two groups are very closely located together on chromosome 4 and are inherited as a haplotype.
The MN blood group in humans is under the control of a pair of co-dominantalleles, LM and LN. Most people in the Inuit population are M/M, while this genotype is rare among Aborigines. In fact, they tend to possess the opposite genotype (N/N).[citation needed]
The MN blood group system is under the control of an autosomal locus found on chromosome 4, with two alleles designated LM and LN. The blood type is due to a glycoprotein present on the surface of a red blood cell (RBC), which behaves as a native antigen. Phenotypic expression at this locus is codominant because an individual may exhibit either one or both antigenic substances. Frequencies of the two alleles vary widely among human populations.[5]
M+ and N+ RBCs are common (75% of population) and M+N+ cells are the most common genotype (50% of population). These antigens were an early discovery and are some of the oldest blood antigens known after the ABO system. They were first described by Karl Landsteiner and Philip Levine in 1927. Anti-M and anti-N antibodies are usually IgM and are rarely associated with transfusion reactions.[citation needed]
Anti-N is sometimes seen in dialysis patients due to cross-reactions with the residual formaldehyde from sterilizing the equipment. This is usually irrelevant for transfusion since this variant of the antibody does not react at body temperature.[citation needed]
The S antigen is relatively common (~55% of the population) and the s antigen is very common (~89% of the population). Anti-S and anti-s can cause hemolytic transfusion reactions and hemolytic disease of the newborn.The U antigen is a high incidence antigen, occurring in more than 99.9% of the population. The U was originally short for "Universal", though this is not the case. U negative RBCs can be found in people of African descent. This mutation in red cell surface structure also makes the RBCs S- and s-. Anti-U has been associated with both hemolytic transfusion reactions and hemolytic disease of the newborn.[citation needed]
The other 41 identified antigens in the MNS group are low incidence, such as He (0.8% of the population) or high incidence, such as ENa (>99.9% of the population).
Antigens of the MNS system are located on one of two glycoproteins: glycophorin A (GPA, CD235A) and glycophorin B (GPB, CD235B).[6] Each glycoprotein crosses the membrane once and has an external N-terminal domain (varying in length from 44 amino acids for GPB to 72 amino acids in length for GPA)[6] as well as a C-terminal cytosolic domain (GPB, 8 amino acids in length; GPA, 36 amino acids in length).[6]
MNS antibodies display dosage (they react stronger against cells which are homozygous vs heterozygous for the antigen in question).
Anti-M and anti-N antibodies are naturally occurring, cold-reacting IgM-class antibodies.[7]
Anti-M and anti-N are generally clinically insignificant.
Anti-S, anti-s and anti-U antibodies are acquired following exposure (via pregnancy or past transfusion with blood products) and are warm-reacting IgG-class antibodies.[7]
Anti-S, anti-s and anti-U are usually clinically significant.
Mark E. Brecher, Editor (2005), AABB Technical Manual, 15th edition, Bethesda, MD: AABB, ISBN1-56395-196-7, p. 336-340
Denise M. Harmening (1999), Modern Blood Banking and Transfusion Practices, Philadelphia, PA: F.A. Davis Company, p. 164-169
^Daniels G, Flegel WA, Fletcher A, et al. International Society of Blood Transfusion Committee on Terminology for Red Cell Surface Antigens: Cape Town Report. Vox Sang 2007; 92: 250-3.
^Poole J, Daniels G. Blood Group Antibodies and Their Significance in Transfusion Medicine. Transfus Med Rev 2007; 21: 58-71.
^Daniels G. Human Blood Groups. 2nd Ed. Oxford: Blackwell Science, 2002.
^Ralph H. Kathan and Anthony Adamany. 1967. Comparison of Human MM, NN, and MN Blood Group Antigens. The Journal of Biological Chemistry, 242, 1736-1722.
